Medifast

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm’s product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Medifast reports Q4 revenue decline, focuses on cost management

Medifast's Q4 2022 performance saw revenue decline but strong cost management and cash generation.
Challenges include revenue outlook for Q1 2023 and competitive landscape in weight loss and coaching markets.
Opportunities lie in capital allocation strategies, maintaining shareholder value, and adapting to market trends.
Overall, Medifast remains focused on long-term growth, financial stability, and delivering on its mission.

Medifast surpasses Q1 expectations, eyes growth amid operational tweaks

Medifast's Q1 2023 performance exceeded expectations, with a focus on revenue growth and cost control measures.
Despite challenges like decreased active coaches, the company is well-positioned with a strong financial standing and growth initiatives.
Opportunities in customer acquisition, cost-saving efforts, market expansion, and innovative solutions pave the way for future success.
Guidance for Q2 2023 reflects a strategic approach to balancing growth and profitability amidst market dynamics and operational changes.

Medifast reports Q2 revenue decline, eyes sustainable growth strategies

Medifast navigated challenges in Q2 2023 with improved operating margin and strategic market exits.
The company's focus on new growth initiatives and cost-saving measures reflects adaptability to market dynamics.
While facing revenue declines and competitive pressures, Medifast aims for sustainable growth with clear targets.
Exploration of medically supported weight loss solutions and new product lines offer avenues for future expansion.

Medifast reports resilient Q3 performance, eyes growth through diversification

Medifast's Q3 performance reflects resilience amid revenue decline, with a focus on operational efficiency and financial strength. While facing challenges in revenue and expense management, the company remains agile and proactive in exploring growth opportunities through market expansion and social responsibility initiatives.

Medifast transitions to health and wellness focus amidst revenue challenges

Medifast is navigating challenges in customer acquisition and macro factors while focusing on becoming a diversified health and wellness company.
The company's strategic collaboration with Life MD and new product offerings position it for growth.
While Q4 2023 saw a revenue decrease, Medifast's improved gross profit margin and cost-saving initiatives demonstrate operational efficiency.
Investors should monitor the impact of increased marketing spending on operating margin and EPS in the coming years.

Medifast faces revenue decline due to weight loss medication trends

Medifast's Q1 2024 performance reflects challenges in revenue and income, driven by difficulties in customer acquisition amidst weight loss medication trends.
Despite the decline, the company demonstrated operational efficiency with improved gross profit margins and cost management.
Investments in marketing and collaborations present opportunities for future growth and market expansion, signaling a strategic focus on long-term success.
Navigating market challenges while capitalizing on opportunities will be crucial for Medifast's resilience and competitiveness in the weight loss industry.

Medifast reports Q2 losses, focuses on growth strategies and cost management

Medifast's Q2 2024 performance reflects a challenging period marked by revenue and profit declines, offset by margin improvements and cost reductions.
The company's strategic initiatives aim to drive long-term growth and enhance operational efficiency amidst macroeconomic headwinds and lower coach productivity.
While facing financial setbacks, Medifast's focus on targeted advertising, product diversification, and cost management signifies a proactive stance towards future recovery and growth.

Medifast adapts to industry changes with tailored programs and innovations

Medifast's Q3 2024 performance reflected revenue and net income declines, highlighting challenges in the weight loss industry.
Despite these challenges, the company's strategic focus on tailored programs, strong financial position, and new product launches indicate a proactive approach to addressing market dynamics.
Opportunities in clinical studies, new product launches, and financial strength position Medifast for potential growth and market expansion in the future.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medifast, Inc. engages in the provision of healthy living products and programs. It offers the OPTAVIA brand, a lifestyle solution centered on developing new healthy habits through smaller, foundational changes called micro-habits. The firm's product line includes bars, bites, pretzels, puffs, cereal crunch, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups. The company was founded by William Vitale in 1981 and is headquartered in Baltimore, MD.

By the end of 2021, Medifast's revenue grew by 63.2%, and the number of coaches grew by 35.3% year-over-year to 59.8 thousand.

Medifast: A Growth Company For Value Investors

Agnico Eagle Mines

Broadcom

Canadian Natural Resources

Cohen & Steers

Coterra Energy

Enterprise Products Partners

Global Industrial Co

Illinois Tool Works

Leggett & Platt

Magellan Midstream Partners

Procter & Gamble

Silicon Motion Technology

T. Rowe Price Group

Texas Instruments

Dividends are a powerful tool that investors should employ to achieve a balance of total return and low volatility.

My Top 10 Dividend Payer Picks For March

Medifast's (MED) fourth-quarter 2021 results reflect stellar earnings and revenues, courtesy of continued strength in OPTAVIA. Sales and earnings view for 2022 reflect year-over-year growth.

Medifast (MED) Q4 Earnings Beat, Strength in OPTAVIA Key Driver

Medifast's (MED) CEO Dan Chard on Q4 2021 Results - Earnings Call Transcript

Medifast (MED) delivered earnings and revenue surprises of 8.99% and 0.49%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Medifast (MED) Surpasses Q4 Earnings and Revenue Estimates

BALTIMORE, Feb. 23, 2022 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities,  OPTAVIA®, today reported results for the fourth quarter and full year ended December 31, 2021. Fourth Quarter 2021 Highlights Compared to the Prior-Year Period Revenue increased 42.6% to $377.8 million 35.3% growth in the number of active earning OPTAVIA Coaches to 59,800 Revenue per active earning OPTAVIA Coach increased 6.6% to $6,321 Net income increased 21.5% to $34.0 million Earnings per diluted share ("EPS") of $2.91, an increase of 23.3% Full Year 2021 Highlights Compared to the Prior-Year Period Revenue increased 63.2% to $1.526 billion Net income increased 59.5% to $164.0 million EPS of $13.89, an increase of 60.0% Cash, cash equivalents and investment securities of $109.5 million and the company remains free of interest-bearing debt as of December 31, 2021 "2021 was another outstanding year for Medifast, with record revenue and earnings fueled by continued growth across our independent OPTAVIA Coaches and Clients.

Medifast, Inc. Announces Fourth Quarter and Full Year 2021 Financial Results

BALTIMORE, Feb. 22, 2022 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced it has been named among Forbes' 2022 list of America's Best Mid-Sized Companies – ranking 23 out of the 100 companies listed. The annual list recognizes top-performing mid-sized companies based on earnings growth, sales growth, return on equity and total stock return for the latest 12 months available and over the last five years.

Medifast Named One of America's Best Mid-Sized Companies by Forbes

Medifast's (MED) fourth-quarter 2021 results are likely to reflect strength in the OPTAVIA lifestyle solution and coaching support system and the benefits from growth-related initiatives.

Medifast (MED) Queued for Q4 Earnings: Key Things to Note

Charles River Laboratories

JAKKS Pacific

Phibro Animal Health

Tempur Sealy International

Stocks with rising P/E often proves to be an intriguing investing idea.

Land on 5 Winning Stocks With the Overlooked Rising P/E Trick

BALTIMORE, Feb. 11, 2022 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, will announce financial results for the fourth quarter and full year ended December 31, 2021 on Wednesday, February 23, 2022, after market close. The Company will host a conference call to discuss the results with additional comments and details.

Medifast, Inc. to Announce Financial Results for the Fourth Quarter and Full Year Ended December 31, 2021

Medifast (MED) could produce exceptional returns because of its solid growth attributes.

3 Reasons Growth Investors Will Love Medifast (MED)

Asbury Automotive Group

Polaris

Zymeworks Inc

Want to try a different approach? Tap five stocks with increasing P/E ratios such as MEDIFAST (MED), JAKKS Pacific (JAKK), Asbury Automotive Group (ABG), Zymeworks (ZYME) and Polaris (PII).

Bank on Rising P/E Investing With These 5 Top-Ranked Stocks

Medifast (MED) has been benefiting from the strength of its OPTAVIA lifestyle solution and coaching support system, as well as efficient technological investments.

Medifast (MED) Looks Great on OPTAVIA, Strategic Investments

9m'21 revenues growing by 70% compared to previous year.

Medifast: A Unique Marketing Model That Welcomes The Well-Being Of All Stakeholders

Medifast (MED) possesses solid growth attributes, which could help it handily outperform the market.

Is Medifast (MED) a Solid Growth Stock? 3 Reasons to Think " Yes "

Medifast (MED) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

What Makes Medifast (MED) a New Buy Stock

Here is how Medifast (MED) and SunOpta (STKL) have performed compared to their sector so far this year.

Is Medifast (MED) Stock Outpacing Its Consumer Staples Peers This Year?

BALTIMORE, Dec. 29, 2021 /PRNewswire/ -- Medifast, Inc. (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, announced today that Dan Chard, Chairman and Chief Executive Officer, and Jim Maloney, Chief Financial Officer, will present at the 2022 ICR Conference on Tuesday, January 11, 2022.  The presentation is scheduled to begin at 2:30 p.m.

Medifast, Inc. to Present at the 2022 ICR Conference

Medifast (MED) has been gaining on strength of its OPTAVIA lifestyle solution and coaching support system, which was a major driver in the third quarter.

Medifast (MED) Gains on OPTAVIA Strength, SG&A Costs Rise

BALTIMORE, Dec. 13, 2021 /PRNewswire/ -- Medifast (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA®, today released findings from a new survey* that revealed a shift in how U.S. adults are approaching New Year's resolutions. According to the survey, only 10% of U.S. adults stick with their resolutions and nearly half (47%) of all resolutions are broken within the first month.

Less than Half of U.S. Adults Plan on Setting 2022 New Year's Resolutions

BALTIMORE, Dec. 10, 2021 /PRNewswire/ -- Medifast  (NYSE: MED), the global company behind one of the fastest-growing health and wellness communities, OPTAVIA ®, today announced that it was named to FORTUNE Magazine's list of the top 100 Fastest-Growing Companies for a third straight year . Medifast ranked number 22 and is the only health and wellness company included on the highly regarded list.

Medifast Named to FORTUNE's 2021 Fastest-Growing Companies List

The company's management targets sustainable 15% growth in revenues and operating income over the long term.

Medifast: A Unique Opportunity For Both Growth And Value Investors

Autohome

Chemed

Dick's Sporting Goods

Ensign Group

Evercore

Gentex

Garmin

Houlihan Lokey

Johnson Outdoors

Kforce

Lithia Motors

Logitech

PulteGroup

The American Association of Individual Investors (AAII) publishes monthly tips for members on-line. Their November Journal featured these thirty Buffett-worthy candidates by one of Buffett's closest followers, Robert Hagstrom.

Tracking Warren Buffett's Future Dividend Picks: 21 From AAII's Hagstrom Screen

Griffon

MKS Instruments

Radiant Logistics

As of Nov. 18, the following stocks look underestimated by the market, as their price-earnings ratios without non-recurring items (NRI) trade below 20 while their price-earnings to growth (PEG) ratios trade near or below 1.

4 Stocks That Look Like Potential Bargains

Is Medifast (MED) a great pick from the value investor's perspective right now? Read on to know more.

News for Medifast Stock (MED)